UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission File Number: 001-41845

 

DOMINARI HOLDINGS INC.
(Exact name of registrant as specified in its charter)

 

Delaware   52-0849320
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

725 5th Avenue, 22nd Floor, New York, NY 10022
(Address of principal executive offices and Zip Code)

 

(212) 393-4540
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock ($0.0001 par value per share)   DOMH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

 

As of May 7, 2024, there were 5,995,065 shares of the Company’s common stock issued and 5,934,917 shares outstanding.

 

 

 

 

 

 

DOMINARI HOLDINGS INC.

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024

 

TABLE OF CONTENTS

 

   

Page 

     
Part I - Financial Information  
     
Item 1. Financial Statements (Unaudited) 1
     
  Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023 1
     
  Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 (Unaudited) 2
     
  Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three months ended March 31, 2024 and 2023 (Unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (Unaudited) 4
     
  Notes to the Condensed Consolidated Financial Statements (Unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
     
Item 4. Controls and Procedures 19
     
Part II - Other Information  
     
Item 1. Legal Proceedings 20
     
Item 1A. Risk Factors 20
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
     
Item 3. Defaults Upon Senior Securities 20
     
Item 4. Mine Safety Disclosures 20
     
Item 5. Other Information 20
     
Item 6. Exhibits 20
     
Signatures 21

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

(Unaudited)

 

   March 31,   December 31, 
   2024   2023 
   (Unaudited)     
ASSETS        
Current assets        
Cash and cash equivalents  $1,956   $2,833 
Marketable securities   5,123    13,547 
Deposits with clearing broker   14,094    7,687 
Prepaid expenses and other assets   2,230    898 
Notes receivable, at fair value - current portion   1,955    3,177 
Total current assets   25,358    28,142 
           
Property and equipment, net   317    344 
Notes receivable, at fair value - non-current portion   1,128    1,129 
Long-term equity investments   21,691    24,150 
Right-of-use assets   3,242    3,335 
Security deposit   458    458 
Total assets  $52,194   $57,558 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued expenses  $840   $1,036 
Accrued salaries and benefits   -    51 
Accrued commissions   295    77 
Lease liability - current   419    421 
Other current liability   42    22 
Total current liabilities   1,596    1,607 
           
Lease liability, less current portion   2,929    3,028 
Total liabilities   4,525    4,635 
           
Stockholders’ equity          
Preferred stock, $.0001 par value, 50,000,000 authorized
   
 
    
 
 
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding as of March 31, 2024 and December 31, 2023; liquidation value of $0.0001 per share   
-
    
-
 
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding as of March 31, 2024 and December 31, 2023; liquidation value of $0.0001 per share   
-
    
-
 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 shares issued as of March 31, 2024 and December 31, 2023; 5,934,917 shares outstanding as of March 31, 2024 and December 31, 2023   
-
    
-
 
Additional paid-in capital   262,374    262,187 
Treasury stock, as of cost, 60,148 shares as of March 31, 2024 and December 31, 2023   (501)   (501)
Accumulated deficit   (214,204)   (208,763)
Total stockholders’ equity   47,669    52,923 
Total liabilities and stockholders’ equity  $52,194   $57,558 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

1

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

 

   Three Months Ended
March 31,
 
   2024   2023 
Revenue  $1,367   $
-
 
           
Operating costs and expenses          
General and administrative   4,172    3,834 
Total operating expenses   4,172    3,834 
Loss from operations   (2,805)   (3,834)
           
Other income (expenses)          
Interest income   164    137 
Gain (loss) on marketable securities, net   574    (65)
Realized and unrealized gain and loss on notes receivable, net   (915)   
-
 
Change in fair value of long-term equity investments   (2,459)   
-
 
Total other income (expenses)   (2,636)   72 
Net loss  $(5,441)  $(3,762)
           
Net loss per share, basic and diluted          
Basic and Diluted
  $(0.91)  $(0.71)
           
Weighted average number of shares outstanding, basic and diluted          
Basic and Diluted
   5,995,065    5,305,513 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

2

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

 

For the Three Months Ended March 31, 2024 and 2023  

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Total
Stockholders'
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at December 31, 2023   4,659   $
-
    5,995,065   $
       -
   $262,187    60,148   $(501)  $(208,763)  $52,923 
Stock-based compensation   -    
-
    -    
-
    187    -    
-
    
-
    187 
Net loss   -    
-
    -    
-
    
-
    -    
-
    (5,441)   (5,441)
Balance at March 31, 2024   4,659   $
      -
    5,995,065   $
-
   $262,374    60,148   $(501)  $(214,204)  $47,669 

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at December 31, 2022   4,659   $
       -
    5,485,096   $
        -
   $262,970    468,017   $(3,322)  $(185,881)  $73,767 
Stock-based compensation   -    
-
    -    
-
    5    -    
-
    
-
    5 
Cancellation of common stock   
-
    
-
    (25,000)   
-
    
-
    
-
    
-
    
-
    
                     -
 
Purchase of treasury stock   -    
-
    -    
-
    
-
    236,630    (939)   
-
    (939)
Retirement of treasury stock   
-
    
-
    (644,499)   
-
    (3,760)   (644,499)   3,760    
-
    
-
 
Net loss   -    
-
    -    
-
    
-
    -    
-
    (3,762)   (3,762)
Balance at March 31, 2023   4,659   $
-
    4,815,597   $
-
   $259,215    60,148   $(501)  $(189,643)  $69,071 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

 

   Three Months Ended
March 31,
 
   2024   2023 
Cash flows from operating activities        
Net loss  $(5,441)  $(3,762)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of right-of-use assets   93    92 
Depreciation   26    7 
Change in fair value of long-term equity investments   2,459    
-
 
Stock-based compensation   187    5 
Realized loss on marketable securities   93    56 
Unrealized (gain) loss on marketable securities   (473)   130 
Realized and unrealized gain and loss on notes receivable, net   915    
-
 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   6    (221)
Prepaid acquisition cost   
-
    301 
Clearing broker deposits   (6,407)   
-
 
Accounts payable and accrued expenses   (196)   (19)
Accrued salaries and benefits   (51)   (528)
Accrued commissions   218    
-
 
Lease liabilities   (101)   7 
Other current liabilities   20    3 
Notes receivable, at fair value – net interest accrued   58    (62)
Net cash used in operating activities   (8,594)   (3,991)
           
Cash flows from investing activities          
Purchase of marketable securities   (24)   (17,519)
Sale of marketable securities   8,829    68 
Purchase of fixed assets   
-
    (361)
Acquisition of FPS, net of cash acquired and receivable owed from FPS   
-
    (1,149)
Collection of principal on notes receivable   250    250 
Loans to employees   (1,340)   
-
 
Collection of loans to employees   2    
-
 
Net cash provided by (used in) investing activities   7,717    (18,711)
           
Cash flows from financing activities          
Purchase of treasury stock   
-
    (939)
Net cash used in financing activities   
-
    (939)
           
Net decrease in cash and cash equivalents and restricted cash   (877)   (23,641)
Cash and cash equivalents, beginning of period   2,833    33,174 
           
Cash and cash equivalents, end of period  $1,956   $9,533 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

 

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the SEC.   Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial.  The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests.   Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

 

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

 

5

 

 

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2023 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023, and the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $14.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of March 31, 2024.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

 

6

 

 

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet.

 

Other revenue includes placement agent services in the equity capital markets for privately held companies distributing private equity. Placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the membership interest offering at that point.

 

Long-term equity investments

 

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the Company. 

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2022-03.

 

7

 

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements. 

 

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
March 31,
 
   2024   2023 
Realized loss  $(93)  $(56)
Unrealized gain (loss)   473    (130)
Dividend income   193    121 
Total  $574   $(65)

 

Note 5. Long-Term Equity Investments

 

The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2024, and December 31, 2023 ($ in thousands):

 

   Cost Basis
as of
March 31,
2024
and December 31,
2023
   March 31,
2024
   December 31,
2023
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    813    1,033 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    2,626    3,500 
Investment in Tesspay**   1,240    2,981    2,679 
Investment in SpaceX*   3,500    3,500    4,867 
Investment in Databricks*   1,200    842    842 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    -    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $21,691   $24,150 

   

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

 

8

 

 

Investment in SpaceX

 

The Company redeemed its entire investment in the portfolio company during April 2024 in exchange for return of cost basis of $3.5 million.

 

Investment in Unusual Machines

 

Unusual Machines, Inc, an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of $4 per share and the shares began trading on the NYSE American under the ticker symbol “UMAC”. As of March 31, 2024 the Company valued its investment in Unusual Machines based on UMAC’s market price.

 

Note 6. Notes Receivable

 

The following table presents the Company’s notes receivable as of March 31, 2024 and December 31, 2023 ($ in thousands):

 

March 31, 2024

 

   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note   12/2/2024  8%  $816   $
-
   $816 
Raefan Industries LLC   12/31/2024  8%  $389   $751   $1,139 
American Innovative Robotics    04/01/2027  8%  $1,106   $22   $1,128 
                      
Notes receivable, at fair value - current portion                  $1,955 
                      
Notes receivable, at fair value - non-current portion                  $1,128 

 

December 31, 2023

 

   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note  12/2/2024  8%  $1,006   $58   $1,064 
Raefan Industries LLC   12/31/2024  8%  $1,363   $751   $2,114 
American Innovative Robotics   04/01/2027  8%  $1,106   $22   $1,129 
                      
Notes receivable, at fair value - current portion                  $3,177 
                      
Notes receivable, at fair value - non-current portion                  $1,129 

 

Convergent Therapeutics, Inc.

 

The Company recorded principal repayment of approximately $0.3 million, interest income of approximately $63,000 and an unrealized gain on the note of approximately $60,000 on the Convergent Convertible Note for the three months ended March 31, 2024.

 

Raefan Industries LLC

  

The Company recorded a realized loss as a result of directly writing off approximately $1.0 million of principal, which the Company deemed uncollectible during the three months ended March 31, 2024.

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $22,000, and an unrealized loss on the note of approximately $1,000 on the Robotics Promissory Note for the three months ended March 31, 2024.

 

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

9

 

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2024, and December 31, 2023 ($ in thousands): 

  

   Fair value measured as of March 31, 2024 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $5,123   $5,123   $
                -
   $
-
 
Total marketable securities  $5,123   $5,123   $
-
   $
-
 
Notes receivable at fair value, current portion  $1,955   $
-
   $
-
   $1,955 
Notes receivable at fair value, non-current portion  $1,128   $
-
   $
-
   $1,128 

 

   Fair value measured as of December 31, 2023 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $13,547   $13,547   $
                -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

   

Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (250)
Realized and unrealized gain and loss on note receivable, net   (915)
Change in interest receivable   (57)
Notes receivable at fair value, current portion at March 31, 2024  $1,955 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at March 31, 2024  $1,128 

 

10

 

 

Notes Receivable at fair value

   

As of March 31, 2024, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended March 31, 2024.

 

Note 8. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

  

The tables below represent the Company’s lease assets and liabilities as of March 31, 2024:

 

   March 31,
2024
 
Assets:    
Operating lease right-of-use-assets  $3,242 
      
Liabilities:     
Current     
Operating   419 
Long-term     
Operating   2,929 
   $3,348 

 

11

 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   March 31,
2024
   March 31,
2023
 
Weighted-average remaining lease term – operating leases (in years)   6.2    7.2 
Weighted-average discount rate – operating leases   10.0%   10.0%

 

During the three months ended March 31, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations.

 

   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating leases        
Operating lease cost  $           178   $134 
Operating lease expense   178    134 
Short-term lease rent expense   22    30 
Net rent expense  $200   $164 

 

Supplemental cash flow information related to leases were as follows: 

 

   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating cash flows - operating leases  $           187   $34 
Right-of-use assets obtained in exchange for operating lease liabilities  $
-
   $2,796 

 

As of March 31, 2024, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2024   560 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,541 
Less present value discount   (1,193)
Operating lease liabilities  $3,348 

 

12

 

 

Note 9. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2024, and 2023 are as follows: 

 

   As of March 31, 
   2024   2023 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,096    31,193 
Total   1,001,235    476,023 

 

Note 10. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of March 31, 2024, there are 5,995,065 shares of common stock issued and 5,934,917 shares outstanding.

 

Treasury Stock

 

There are 60,148 shares of treasury stock as of March 31, 2024.

 

Warrants

 

A summary of warrant activity for the three months ended March 31, 2024, is presented below:

 

   Warrants   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 
Granted   
-
   $
-
    
-
    
-
 
Outstanding as of March 31, 2024   444,796   $29.25    
-
    1.95 

  

Restricted Stock Awards

 

A summary of restricted stock awards activity for the three months ended March 31, 2024, is presented below:

 

   Number of Restricted Stock Awards   Weighted Average Grant Day Fair Value 
Nonvested at December 31, 2023   136,309   $2.26 
Granted   
-
   $
-
 
Vested   
-
   $
-
 
Nonvested at March 31, 2024   136,309   $2.26 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $75,000 and $257 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

13

 

 

As of March 31, 2024, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2024, is presented below:

  

   Number of Shares   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2023   420,168   $5.80   $
           -
    9.3 
Employee options expired   (72)  $6,410.74    
-
    
-
 
Outstanding as of March 31, 2024   420,096   $4.71   $
-
    9.0 
Options vested and exercisable   108,666   $8.37   $
-
    8.6 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $0.1 million and $5,000 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.4 million.

 

Note 11. Revenue

 

The following table presents our total revenue disaggregated by revenue type for the three months ended March 31, 2024 and 2023 (in thousands):

 

   Three Months Ended
March 31
 
   2024   2023 
Underwriting  $409   $
-
 
Commissions   310    
-
 
Advisory fees   341    
-
 
Other   307    
-
 
Total  $1,367   $
-
 

 

Note 12. Commitments and Contingencies

 

Legal Proceedings

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

14

 

 

Note 13. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of March 31, 2024, Dominari Securities had net capital of approximately $13.4 million, which was approximately $13.3 million in excess of required minimum net capital of $0.1 million.

 

Note 14. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $0 and $80,000 during the three months ending March 31, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

 

Note 15. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Three Months Ended
March 31, 2024
 
   Dominari
Financial
   Legacy
AIkido
   Consolidated 
Revenue  $1,367   $
-
   $1,367 
Operating Costs               
General and administrative   2,712    1,460   $4,172 
Loss from operations  $(1,345)  $(1,460)  $(2,805)
                
Other income (expenses)               
Other income   
-
    
-
    
-
 
Interest income   137    27    164 
Gain on marketable securities   
-
    574    574 
Realized and unrealized gain and loss on notes receivable, net   
-
    (915)   (915)
    Change in fair value of long-term equity investments        (2,459)   (2,459)
Total other income (expenses)  $137   $(2,773)  $(2,636)
Net loss  $(1,208)  $(4,233)  $(5,441)

 

Note 16. Income Taxes

 

The Company recorded no income tax expense for the three months ended March 31, 2024 and 2023 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of March 31, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

 

Overview

 

Dominari Holdings Inc. (“Dominari”) is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management.  In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as “Company,” “we,” “our” or “us.”

 

Dominari Financial Inc. (“Dominari Financial”), a wholly-owned subsidiary of Dominari Holdings Inc., executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually-registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust (“Fieldpoint”), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities LLC (“Dominari Securities”) and is a wholly-owned subsidiary of Dominari Financial.

 

The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. These biotechnology assets consist of patented technology from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, SARS-CoV-2 and acute lymphoblastic leukemia.  

 

16

 

 

Critical Accounting Estimates

 

We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Our actual results could differ significantly from these estimates under different assumptions and conditions.

 

There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates discussed in the Form 10-K.

 

Refer to Note 3 of the Annual Report for a discussion of our significant accounting policies.

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.

 

Results of Operations

 

Three Months Ended March 31, 2024, compared to the Three Months Ended March 31, 2024

 

During the three months ended March 31, 2024, we recognized approximately $1.4 million in revenue from operations, primarily driven by the commissions and underwriting revenue earned by Dominari Securities. During the three months ended March 31, 2024 and 2023, we incurred a loss from operations of approximately $2.8 million and $3.8 million, respectively. The decrease in loss from operations was primarily general and administrative expenses related to the process of winding down the assets held by Aikido Labs, LLC and was offset by a calendar year loss of $1.3 million from operations in the operations of Dominari Securities.

 

  i. There is a $1.0 million decrease in net operating loss during the three months ended March 31, 2024 compared to same period in 2023, which was driven by $2.3 million decrease in general and administrative expenses for Aikido segment and was offset by $1.3 million loss from operations Dominari Financial segment during the three months ended March 31, 2024.

 

During the three months ended March 31, 2024 and 2023, other (expenses) income was approximately $(2.6) million and $72,000, respectively. The activity for the three months ended March 31, 2024 and 2023, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine and etc.) impacting marketable securities and the change in fair value of long-term equity investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.6 million for the three months ended March 31, 2024. The increase of approximately $0.6 million in gains over the prior period is driven by both market improvement and an increase in sale activity resulting in more realized gains.
     
  ii. Notes receivable – the changes over the three months ended March 31, 2024 and 2023 are a function of observable market transactions which resulted in an increase in unrealized loss of approximately $0.9 million on the adjusted fair value of our notes receivable during the three months ended March 31, 2024.
     

 

 

iii. Long-term equity investments –the changes over the three months ended March 31, 2024 and 2023 are a function of observable market transactions which resulted in an increase in unrealized loss of approximately $2.5 million on the adjusted fair value of the investments during the three months ended March 31, 2024.

 

17

 

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

seeking additional funds raised through the sale of additional securities in the future; and

 

seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $23.8 million as of March 31, 2024. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations.

 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

Cash Flows from Operating Activities

 

For the three months ended March 31, 2024 and 2023, net cash used in operations was approximately $8.6 million and $4.0 million, respectively. The cash used in operating activities for the three months ended March 31, 2024, is primarily attributable to a net loss of approximately $5.4 million and changes in operating assets and liabilities of $6.5 million, partially offset by approximately $2.5 million of change in fair value of long-term equity investment. The cash used in operating activities for the three months ended March 31, 2023, is primarily attributable to a net loss of approximately $3.8 million and changes in operating assets and liabilities of $0.5 million, partially offset by approximately $0.1 million in unrealized losses on marketable securities and approximately $0.06 million of realized loss on marketable securities. 

 

Cash Flows from Investing Activities

 

For the three months ended March 31, 2024 and 2023, net cash provided by (used in) investing activities was approximately $7.7 million and $(18.7) million, respectively. The cash used in investing activities for the three months ended March 31, 2024, primarily resulted from our sales of marketable securities of approximately $8.8 million, partially offset by funds to employee forgivable loan of $1.3 million. The Company also collected approximately $0.3 million in principal related to its short-term notes.  The cash used in investing activities for the three months ended March 31, 2023, primarily resulted from our purchase of marketable securities of approximately $17.5 million and the acquisition of FPS of approximately $1.1 million. The Company also collected approximately $0.3 million in principal related to its short-term notes. 

 

Cash Flows from Financing Activities

 

For the three months ended March 31, 2024, there is no cash flows from financing activities. For the three months ended March 31, 2023, cash used in financing activities was approximately $0.9 million, which reflects the cost for purchase of treasury stock of approximately $0.9 million. 

 

18

 

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

During the quarter ended March 31, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal controls.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonably possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Material Weaknesses in Internal Controls

 

The Company’s management has concluded that our control around the accounting for certain notes receivable accounted for at fair value and certain long-term investments accounted for at fair value or with the equity security measurement alternative was not effectively designed or maintained, and therefore initially were not accounted for correctly. As a result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with accounting principles generally accepted in the United States of America. Management understands that the accounting standards applicable to our financial statements are complex and will seek to enhance controls over its experienced third-party professionals with whom management can consult with respect to accounting issues and remediate this material weakness.

 

Changes in Internal Control Over Financial Reporting

 

We have not made any changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

19

 

  

Part II - Other Information

 

Item 1. Legal Proceedings

 

Many aspects of the Company’s business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company’s business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Annual Report on Form 10-K, which was filed with the SEC on April 1, 2024. Any of our previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Filed herewith.
**Furnished herewith.

 

20

 

  

Signatures

 

Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DOMINARI HOLDINGS INC.
     
Date: May 9, 2024 By: /s/ Anthony Hayes
    Anthony Hayes
    Chief Executive Officer
    (Principal Executive Officer)

 

Date: May 9, 2024 By: /s/ George Way
    George Way
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

21

 

 

0.0001 0.0001 0.71 0.91 5305513 5995065 false --12-31 Q1 0000012239 0000012239 2024-01-01 2024-03-31 0000012239 2024-05-07 0000012239 2024-03-31 0000012239 2023-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2024-03-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-12-31 0000012239 domh:SeriesD1PreferredStockMember 2024-03-31 0000012239 domh:SeriesD1PreferredStockMember 2023-12-31 0000012239 2023-01-01 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-12-31 0000012239 us-gaap:CommonStockMember 2023-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2023-12-31 0000012239 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0000012239 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0000012239 us-gaap:PreferredStockMember 2024-03-31 0000012239 us-gaap:CommonStockMember 2024-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-03-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2024-03-31 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2022-12-31 0000012239 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012239 us-gaap:AociAttributableToNoncontrollingInterestMember 2023-03-31 0000012239 2023-03-31 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2024-03-31 0000012239 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0000012239 2024-02-14 0000012239 domh:InvestmentInKernaHealthIncMember 2024-03-31 0000012239 domh:InvestmentInKernaHealthIncMember 2023-12-31 0000012239 domh:InvestmentInKayaNowMember 2024-03-31 0000012239 domh:InvestmentInKayaNowMember 2023-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2024-03-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2024-03-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-12-31 0000012239 domh:InvestmentInUnusualMachinesMember 2024-03-31 0000012239 domh:InvestmentInUnusualMachinesMember 2023-12-31 0000012239 domh:InvestmentInQxpressMember 2024-03-31 0000012239 domh:InvestmentInQxpressMember 2023-12-31 0000012239 domh:InvestmentInMasterclassMember 2024-03-31 0000012239 domh:InvestmentInMasterclassMember 2023-12-31 0000012239 domh:InvestmentInKrakenMember 2024-03-31 0000012239 domh:InvestmentInKrakenMember 2023-12-31 0000012239 domh:InvestmentInEpicGamesMember 2024-03-31 0000012239 domh:InvestmentInEpicGamesMember 2023-12-31 0000012239 domh:InvestmentInTesspayMember 2024-03-31 0000012239 domh:InvestmentInTesspayMember 2023-12-31 0000012239 domh:InvestmentInSpaceXMember 2024-03-31 0000012239 domh:InvestmentInSpaceXMember 2023-12-31 0000012239 domh:InvestmentInDatabricksMember 2024-03-31 0000012239 domh:InvestmentInDatabricksMember 2023-12-31 0000012239 domh:InvestmentInDiscordMember 2024-03-31 0000012239 domh:InvestmentInDiscordMember 2023-12-31 0000012239 domh:InvestmentInThrasioMember 2024-03-31 0000012239 domh:InvestmentInThrasioMember 2023-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2024-03-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-12-31 0000012239 domh:InvestmentInAndurilMember 2024-03-31 0000012239 domh:InvestmentInAndurilMember 2023-12-31 0000012239 domh:ConvergentTherapeuticsIncMember 2024-01-01 2024-03-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2024-01-01 2024-03-31 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2024-01-01 2024-03-31 0000012239 domh:ConvergentInvestmentMember 2024-01-01 2024-03-31 0000012239 domh:ConvergentInvestmentMember 2024-03-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2024-03-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2024-01-01 2024-03-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2024-03-31 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2024-03-31 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2024-03-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-01-01 2023-12-31 0000012239 domh:ConvergentConvertibleNoteCurrentMember 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-12-31 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-12-31 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-12-31 0000012239 us-gaap:FairValueInputsLevel1Member 2024-03-31 0000012239 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-03-31 0000012239 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-03-31 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-03-31 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0000012239 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000012239 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000012239 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000012239 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000012239 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0000012239 us-gaap:CommonStockMember 2024-03-31 0000012239 domh:RestrictedStockAwardsMember 2024-01-01 2024-03-31 0000012239 domh:RestrictedStockAwardsMember 2023-01-01 2023-03-31 0000012239 us-gaap:WarrantMember 2023-12-31 0000012239 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000012239 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000012239 us-gaap:WarrantMember 2024-03-31 0000012239 2023-01-01 2023-12-31 0000012239 domh:DominariSecuritiesMember 2024-03-31 0000012239 domh:DominariFinancialMember 2024-01-01 2024-03-31 0000012239 domh:LegacyAIkidoPharmaMember 2024-01-01 2024-03-31 0000012239 domh:ConsolidatedMember 2024-01-01 2024-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2024  
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, George Way, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 9, 2024  
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: May 9, 2024  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: May 9, 2024  
   
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

v3.24.1.u1
Cover - shares
3 Months Ended
Mar. 31, 2024
May 07, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Information [Line Items]    
Entity Registrant Name DOMINARI HOLDINGS INC.  
Entity Central Index Key 0000012239  
Entity File Number 001-41845  
Entity Tax Identification Number 52-0849320  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 725 5th Avenue  
Entity Address, Address Line Two 22nd Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
Entity Phone Fax Numbers [Line Items]    
City Area Code (212)  
Local Phone Number 393-4540  
Entity Listings [Line Items]    
Title of 12(b) Security Common Stock ($0.0001 par value per share)  
Trading Symbol DOMH  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   5,934,917
v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 1,956 $ 2,833
Marketable securities 5,123 13,547
Deposits with clearing broker 14,094 7,687
Prepaid expenses and other assets 2,230 898
Notes receivable, at fair value - current portion 1,955 3,177
Total current assets 25,358 28,142
Property and equipment, net 317 344
Notes receivable, at fair value - non-current portion 1,128 1,129
Long-term equity investments 21,691 24,150
Right-of-use assets 3,242 3,335
Security deposit 458 458
Total assets 52,194 57,558
Current liabilities    
Accounts payable and accrued expenses 840 1,036
Accrued salaries and benefits   51
Accrued commissions 295 77
Lease liability - current 419 421
Other current liability 42 22
Total current liabilities 1,596 1,607
Lease liability, less current portion 2,929 3,028
Total liabilities 4,525 4,635
Stockholders’ equity    
Preferred stock value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,995,065 shares issued as of March 31, 2024 and December 31, 2023; 5,934,917 shares outstanding as of March 31, 2024 and December 31, 2023
Additional paid-in capital 262,374 262,187
Treasury stock, as of cost, 60,148 shares as of March 31, 2024 and December 31, 2023 (501) (501)
Accumulated deficit (214,204) (208,763)
Total stockholders’ equity 47,669 52,923
Total liabilities and stockholders’ equity 52,194 57,558
Series D Preferred Stock    
Stockholders’ equity    
Preferred stock value
Series D-1 Preferred Stock    
Stockholders’ equity    
Preferred stock value
v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 5,995,065 5,995,065
Common stock, shares outstanding 5,934,917 5,934,917
Treasury stock, at cost 60,148 60,148
Series D Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 3,825 3,825
Preferred stock, shares outstanding 3,825 3,825
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
Series D-1 Preferred Stock    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 834 834
Preferred stock, shares outstanding 834 834
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
v3.24.1.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue $ 1,367
Operating costs and expenses    
General and administrative 4,172 3,834
Total operating expenses 4,172 3,834
Loss from operations (2,805) (3,834)
Other income (expenses)    
Interest income 164 137
Gain (loss) on marketable securities, net 574 (65)
Realized and unrealized gain and loss on notes receivable, net (915)
Change in fair value of long-term equity investments (2,459)
Total other income (expenses) (2,636) 72
Net loss $ (5,441) $ (3,762)
Net loss per share, basic and diluted    
Basic (in Dollars per share) $ (0.91) $ (0.71)
Weighted average number of shares outstanding, basic and diluted    
Basic (in Shares) 5,995,065 5,305,513
v3.24.1.u1
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Diluted $ (0.91) $ (0.71)
Diluted 5,995,065 5,305,513
v3.24.1.u1
Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 262,970 $ (3,322) $ (185,881) $ 73,767
Balance (in Shares) at Dec. 31, 2022 4,659 5,485,096   468,017    
Stock-based compensation 5 5
Cancellation of common stock
Cancellation of common stock (in Shares) (25,000)      
Purchase of treasury stock $ (939) (939)
Purchase of treasury stock (in Shares)       236,630    
Retirement of treasury stock (3,760) $ 3,760
Retirement of treasury stock (in Shares) (644,499)   (644,499)    
Net loss (3,762) (3,762)
Balance at Mar. 31, 2023 259,215 $ (501) (189,643) 69,071
Balance (in Shares) at Mar. 31, 2023 4,659 4,815,597   60,148    
Balance at Dec. 31, 2023 262,187 $ (501) (208,763) 52,923
Balance (in Shares) at Dec. 31, 2023 4,659 5,995,065   60,148    
Stock-based compensation 187 187
Net loss (5,441) (5,441)
Balance at Mar. 31, 2024 $ 262,374 $ (501) $ (214,204) $ 47,669
Balance (in Shares) at Mar. 31, 2024 4,659 5,995,065   60,148    
v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities    
Net loss $ (5,441) $ (3,762)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of right-of-use assets 93 92
Depreciation 26 7
Change in fair value of long-term equity investments 2,459
Stock-based compensation 187 5
Realized loss on marketable securities 93 56
Unrealized (gain) loss on marketable securities (473) 130
Realized and unrealized gain and loss on notes receivable, net 915
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 6 (221)
Prepaid acquisition cost 301
Clearing broker deposits (6,407)
Accounts payable and accrued expenses (196) (19)
Accrued salaries and benefits (51) (528)
Accrued commissions 218
Lease liabilities (101) 7
Other current liabilities 20 3
Notes receivable, at fair value – net interest accrued 58 (62)
Net cash used in operating activities (8,594) (3,991)
Cash flows from investing activities    
Purchase of marketable securities (24) (17,519)
Sale of marketable securities 8,829 68
Purchase of fixed assets (361)
Acquisition of FPS, net of cash acquired and receivable owed from FPS (1,149)
Collection of principal on notes receivable 250 250
Loans to employees (1,340)
Collection of loans to employees 2
Net cash provided by (used in) investing activities 7,717 (18,711)
Cash flows from financing activities    
Purchase of treasury stock (939)
Net cash used in financing activities (939)
Net decrease in cash and cash equivalents and restricted cash (877) (23,641)
Cash and cash equivalents, beginning of period 2,833 33,174
Cash and cash equivalents, end of period $ 1,956 $ 9,533
v3.24.1.u1
Organization and Description of Business and Recent Developments
3 Months Ended
Mar. 31, 2024
Organization and Description of Business and Recent Developments [Abstract]  
Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the SEC.   Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial.  The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests.   Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

v3.24.1.u1
Liquidity and Capital Resources
3 Months Ended
Mar. 31, 2024
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

v3.24.1.u1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2023 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023, and the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $14.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of March 31, 2024.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

 

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet.

 

Other revenue includes placement agent services in the equity capital markets for privately held companies distributing private equity. Placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the membership interest offering at that point.

 

Long-term equity investments

 

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the Company. 

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2022-03.

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements. 

v3.24.1.u1
Marketable Securities
3 Months Ended
Mar. 31, 2024
Marketable Securities [Abstract]  
Marketable Securities

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended
March 31,
 
   2024   2023 
Realized loss  $(93)  $(56)
Unrealized gain (loss)   473    (130)
Dividend income   193    121 
Total  $574   $(65)
v3.24.1.u1
Long-Term Equity Investments
3 Months Ended
Mar. 31, 2024
Long-Term Equity Investments [Abstract]  
Long-Term Equity Investments

Note 5. Long-Term Equity Investments

 

The Company holds interests in several privately held and publicly traded companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2024, and December 31, 2023 ($ in thousands):

 

   Cost Basis
as of
March 31,
2024
and December 31,
2023
   March 31,
2024
   December 31,
2023
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    813    1,033 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    2,626    3,500 
Investment in Tesspay**   1,240    2,981    2,679 
Investment in SpaceX*   3,500    3,500    4,867 
Investment in Databricks*   1,200    842    842 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    -    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $21,691   $24,150 

   

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investments made in these companies are through both an SPV and direct investments.

 

Investment in SpaceX

 

The Company redeemed its entire investment in the portfolio company during April 2024 in exchange for return of cost basis of $3.5 million.

 

Investment in Unusual Machines

 

Unusual Machines, Inc, an emerging leader in first-person view (FPV) drone technology, closed its initial public offering of common stock on February 14, 2024 at a public offering price of $4 per share and the shares began trading on the NYSE American under the ticker symbol “UMAC”. As of March 31, 2024 the Company valued its investment in Unusual Machines based on UMAC’s market price.

v3.24.1.u1
Notes Receivable
3 Months Ended
Mar. 31, 2024
Notes Receivable [Abstract]  
Notes Receivable

Note 6. Notes Receivable

 

The following table presents the Company’s notes receivable as of March 31, 2024 and December 31, 2023 ($ in thousands):

 

March 31, 2024

 

   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note   12/2/2024  8%  $816   $
-
   $816 
Raefan Industries LLC   12/31/2024  8%  $389   $751   $1,139 
American Innovative Robotics    04/01/2027  8%  $1,106   $22   $1,128 
                      
Notes receivable, at fair value - current portion                  $1,955 
                      
Notes receivable, at fair value - non-current portion                  $1,128 

 

December 31, 2023

 

   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note  12/2/2024  8%  $1,006   $58   $1,064 
Raefan Industries LLC   12/31/2024  8%  $1,363   $751   $2,114 
American Innovative Robotics   04/01/2027  8%  $1,106   $22   $1,129 
                      
Notes receivable, at fair value - current portion                  $3,177 
                      
Notes receivable, at fair value - non-current portion                  $1,129 

 

Convergent Therapeutics, Inc.

 

The Company recorded principal repayment of approximately $0.3 million, interest income of approximately $63,000 and an unrealized gain on the note of approximately $60,000 on the Convergent Convertible Note for the three months ended March 31, 2024.

 

Raefan Industries LLC

  

The Company recorded a realized loss as a result of directly writing off approximately $1.0 million of principal, which the Company deemed uncollectible during the three months ended March 31, 2024.

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $22,000, and an unrealized loss on the note of approximately $1,000 on the Robotics Promissory Note for the three months ended March 31, 2024.

v3.24.1.u1
Fair Value of Financial Assets and Liabilities
3 Months Ended
Mar. 31, 2024
Fair Value of Financial Assets and Liabilities [Abstract]  
Fair Value of Financial Assets and Liabilities

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2024, and December 31, 2023 ($ in thousands): 

  

   Fair value measured as of March 31, 2024 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $5,123   $5,123   $
                -
   $
-
 
Total marketable securities  $5,123   $5,123   $
-
   $
-
 
Notes receivable at fair value, current portion  $1,955   $
-
   $
-
   $1,955 
Notes receivable at fair value, non-current portion  $1,128   $
-
   $
-
   $1,128 

 

   Fair value measured as of December 31, 2023 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $13,547   $13,547   $
                -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

   

Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (250)
Realized and unrealized gain and loss on note receivable, net   (915)
Change in interest receivable   (57)
Notes receivable at fair value, current portion at March 31, 2024  $1,955 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at March 31, 2024  $1,128 

 

Notes Receivable at fair value

   

As of March 31, 2024, the fair value of the notes receivable was measured taking into consideration cost basis, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended March 31, 2024.

v3.24.1.u1
Leases
3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases

Note 8. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

  

The tables below represent the Company’s lease assets and liabilities as of March 31, 2024:

 

   March 31,
2024
 
Assets:    
Operating lease right-of-use-assets  $3,242 
      
Liabilities:     
Current     
Operating   419 
Long-term     
Operating   2,929 
   $3,348 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   March 31,
2024
   March 31,
2023
 
Weighted-average remaining lease term – operating leases (in years)   6.2    7.2 
Weighted-average discount rate – operating leases   10.0%   10.0%

 

During the three months ended March 31, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations.

 

   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating leases        
Operating lease cost  $           178   $134 
Operating lease expense   178    134 
Short-term lease rent expense   22    30 
Net rent expense  $200   $164 

 

Supplemental cash flow information related to leases were as follows: 

 

   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating cash flows - operating leases  $           187   $34 
Right-of-use assets obtained in exchange for operating lease liabilities  $
-
   $2,796 

 

As of March 31, 2024, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining Period Ended December 31, 2024   560 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,541 
Less present value discount   (1,193)
Operating lease liabilities  $3,348 
v3.24.1.u1
Net Loss Per Share
3 Months Ended
Mar. 31, 2024
Net Loss per Share [Abstract]  
Net Loss per Share

Note 9. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2024, and 2023 are as follows: 

 

   As of March 31, 
   2024   2023 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,096    31,193 
Total   1,001,235    476,023 
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock
3 Months Ended
Mar. 31, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Stockholders’ Equity and Convertible Preferred Stock

Note 10. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of March 31, 2024, there are 5,995,065 shares of common stock issued and 5,934,917 shares outstanding.

 

Treasury Stock

 

There are 60,148 shares of treasury stock as of March 31, 2024.

 

Warrants

 

A summary of warrant activity for the three months ended March 31, 2024, is presented below:

 

   Warrants   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 
Granted   
-
   $
-
    
-
    
-
 
Outstanding as of March 31, 2024   444,796   $29.25    
-
    1.95 

  

Restricted Stock Awards

 

A summary of restricted stock awards activity for the three months ended March 31, 2024, is presented below:

 

   Number of Restricted Stock Awards   Weighted Average Grant Day Fair Value 
Nonvested at December 31, 2023   136,309   $2.26 
Granted   
-
   $
-
 
Vested   
-
   $
-
 
Nonvested at March 31, 2024   136,309   $2.26 

 

Stock-based compensation associated with the amortization of restricted stock awards expense was approximately $75,000 and $257 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

As of March 31, 2024, there is approximately $0.2 million unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2024, is presented below:

  

   Number of Shares   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2023   420,168   $5.80   $
           -
    9.3 
Employee options expired   (72)  $6,410.74    
-
    
-
 
Outstanding as of March 31, 2024   420,096   $4.71   $
-
    9.0 
Options vested and exercisable   108,666   $8.37   $
-
    8.6 

 

Stock-based compensation associated with the amortization of stock option expense was approximately $0.1 million and $5,000 for the three months ended March 31, 2024, and 2023, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $0.4 million.

v3.24.1.u1
Revenue
3 Months Ended
Mar. 31, 2024
Revenue [Abstract]  
Revenue

Note 11. Revenue

 

The following table presents our total revenue disaggregated by revenue type for the three months ended March 31, 2024 and 2023 (in thousands):

 

   Three Months Ended
March 31
 
   2024   2023 
Underwriting  $409   $
-
 
Commissions   310    
-
 
Advisory fees   341    
-
 
Other   307    
-
 
Total  $1,367   $
-
 
v3.24.1.u1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2024
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 12. Commitments and Contingencies

 

Legal Proceedings

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

v3.24.1.u1
Regulatory
3 Months Ended
Mar. 31, 2024
Regulatory [Abstract]  
Regulatory

Note 13. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of March 31, 2024, Dominari Securities had net capital of approximately $13.4 million, which was approximately $13.3 million in excess of required minimum net capital of $0.1 million.

v3.24.1.u1
Related Party Transaction
3 Months Ended
Mar. 31, 2024
Related Party Transaction [Abstract]  
Related Party Transaction

Note 14. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, was previously a member of the board of directors of Revere. The Company incurred fees of approximately $0 and $80,000 during the three months ending March 31, 2024 and 2023, respectively. These fees were included in general and administrative expenses in the unaudited condensed consolidated statements of operations.

v3.24.1.u1
Segment Reporting
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting

Note 15. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations.

 

   Three Months Ended
March 31, 2024
 
   Dominari
Financial
   Legacy
AIkido
   Consolidated 
Revenue  $1,367   $
-
   $1,367 
Operating Costs               
General and administrative   2,712    1,460   $4,172 
Loss from operations  $(1,345)  $(1,460)  $(2,805)
                
Other income (expenses)               
Other income   
-
    
-
    
-
 
Interest income   137    27    164 
Gain on marketable securities   
-
    574    574 
Realized and unrealized gain and loss on notes receivable, net   
-
    (915)   (915)
    Change in fair value of long-term equity investments        (2,459)   (2,459)
Total other income (expenses)  $137   $(2,773)  $(2,636)
Net loss  $(1,208)  $(4,233)  $(5,441)
v3.24.1.u1
Income Taxes
3 Months Ended
Mar. 31, 2024
Income Taxes [Abstract]  
Income Taxes

Note 16. Income Taxes

 

The Company recorded no income tax expense for the three months ended March 31, 2024 and 2023 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of March 31, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ (5,441) $ (3,762)
v3.24.1.u1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.1.u1
Accounting Policies, by Policy (Policies)
3 Months Ended
Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheet as of March 31, 2024, condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2024 and 2023, and the condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024 or for any future interim period. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023.

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Deposits with clearing broker

Deposits with clearing broker

Deposits with Dominari Securities’ clearing broker consisted of approximately $14.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of March 31, 2024.

Leases

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 8 - Leases).

 

Revenue

Revenue

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”)Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.
Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
Account advisory fees are earned in connection with investment advisory services.  Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Condensed Consolidated Balance Sheet.
Other revenue includes placement agent services in the equity capital markets for privately held companies distributing private equity. Placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the membership interest offering at that point.
Long-term equity investments

Long-term equity investments

The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments—Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Equity securities without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the Company. 

Recently adopted accounting standards

Recently adopted accounting standards

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted ASU 2022-03 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2022-03.

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2023-01 on January 1, 2024. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements. 

v3.24.1.u1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2024
Marketable Securities [Abstract]  
Schedule of Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2024 and 2023, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):
   Three Months Ended
March 31,
 
   2024   2023 
Realized loss  $(93)  $(56)
Unrealized gain (loss)   473    (130)
Dividend income   193    121 
Total  $574   $(65)
v3.24.1.u1
Long-Term Equity Investments (Tables)
3 Months Ended
Mar. 31, 2024
Long-Term Equity Investments [Abstract]  
Schedule of Long-Term Investments The following table presents the Company’s long-term investments as of March 31, 2024, and December 31, 2023 ($ in thousands):
   Cost Basis
as of
March 31,
2024
and December 31,
2023
   March 31,
2024
   December 31,
2023
 
Investment in Kerna Health Inc  $2,140   $4,940   $4,940 
Investment in Kaya Now   1,500    
-
    
-
 
Investment in Tevva Motors   1,972    2,794    2,794 
Investment in ASP Isotopes   1,300    
-
    
-
 
Investment in Unusual Machines   1,075    813    1,033 
Investment in Qxpress*   1,000    1,000    1,000 
Investment in Masterclass*   170    170    170 
Investment in Kraken*   597    597    597 
Investment in Epic Games*   3,500    2,626    3,500 
Investment in Tesspay**   1,240    2,981    2,679 
Investment in SpaceX*   3,500    3,500    4,867 
Investment in Databricks*   1,200    842    842 
Investment in Discord*   476    476    476 
Investment in Thrasio*   300    -    300 
Investment in Automation Anywhere*   476    476    476 
Investment in Anduril*   476    476    476 
Total  $20,922   $21,691   $24,150 
*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
**Investments made in these companies are through both an SPV and direct investments.

 

v3.24.1.u1
Notes Receivable (Tables)
3 Months Ended
Mar. 31, 2024
Notes Receivable [Abstract]  
Schedule of Notes Receivable The following table presents the Company’s notes receivable as of March 31, 2024 and December 31, 2023 ($ in thousands):
   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note   12/2/2024  8%  $816   $
-
   $816 
Raefan Industries LLC   12/31/2024  8%  $389   $751   $1,139 
American Innovative Robotics    04/01/2027  8%  $1,106   $22   $1,128 
                      
Notes receivable, at fair value - current portion                  $1,955 
                      
Notes receivable, at fair value - non-current portion                  $1,128 
   Maturity Date  Stated Interest Rate  Principal Amount   Interest Receivable   Fair Value 
Notes receivable, at fair value                     
Convergent convertible note  12/2/2024  8%  $1,006   $58   $1,064 
Raefan Industries LLC   12/31/2024  8%  $1,363   $751   $2,114 
American Innovative Robotics   04/01/2027  8%  $1,106   $22   $1,129 
                      
Notes receivable, at fair value - current portion                  $3,177 
                      
Notes receivable, at fair value - non-current portion                  $1,129 
v3.24.1.u1
Fair Value of Financial Assets and Liabilities (Tables)
3 Months Ended
Mar. 31, 2024
Fair Value of Financial Assets and Liabilities [Abstract]  
Schedule of Assets and Liabilities are Measured at Fair Value The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2024, and December 31, 2023 ($ in thousands):
   Fair value measured as of March 31, 2024 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $5,123   $5,123   $
                -
   $
-
 
Total marketable securities  $5,123   $5,123   $
-
   $
-
 
Notes receivable at fair value, current portion  $1,955   $
-
   $
-
   $1,955 
Notes receivable at fair value, non-current portion  $1,128   $
-
   $
-
   $1,128 
   Fair value measured as of December 31, 2023 
   Total at December 31,   Quoted prices in active markets   Significant other observable inputs   Significant unobservable inputs 
   2023   (Level 1)   (Level 2)   (Level 3) 
Assets                
Marketable securities:                    
Equities  $13,547   $13,547   $
                -
   $
-
 
Total marketable securities  $13,547   $13,547   $
-
   $
-
 
Notes receivable at fair value, current portion  $3,177   $
-
   $
-
   $3,177 
Notes receivable at fair value, non-current portion  $1,129   $
-
   $
-
   $1,129 
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):
Notes receivable at fair value, current portion at December 31, 2023  $3,177 
Collection of principal outstanding   (250)
Realized and unrealized gain and loss on note receivable, net   (915)
Change in interest receivable   (57)
Notes receivable at fair value, current portion at March 31, 2024  $1,955 
      
Notes receivable at fair value, non-current portion at December 31, 2023  $1,129 
Unrealized loss on notes receivable   (1)
Notes receivable at fair value, non-current portion at March 31, 2024  $1,128 

 

v3.24.1.u1
Leases (Tables)
3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Lease Assets and Liabilities The tables below represent the Company’s lease assets and liabilities as of March 31, 2024:
   March 31,
2024
 
Assets:    
Operating lease right-of-use-assets  $3,242 
      
Liabilities:     
Current     
Operating   419 
Long-term     
Operating   2,929 
   $3,348 

 

Schedule of Summarize Quantitative Information about the Company’s Operating Leases The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:
   March 31,
2024
   March 31,
2023
 
Weighted-average remaining lease term – operating leases (in years)   6.2    7.2 
Weighted-average discount rate – operating leases   10.0%   10.0%
Schedule of Lease Expense to Current Period Operations During the three months ended March 31, 2024 and 2023, the Company recorded approximately $0.2 million, respectively, of lease expense to current period operations.
   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating leases        
Operating lease cost  $           178   $134 
Operating lease expense   178    134 
Short-term lease rent expense   22    30 
Net rent expense  $200   $164 
Schedule of Supplemental Cash Flow Information Related to Leases Supplemental cash flow information related to leases were as follows:
   Three Months
Ended
   Three Months
Ended
 
   March 31,
2024
   March 31,
2023
 
Operating cash flows - operating leases  $           187   $34 
Right-of-use assets obtained in exchange for operating lease liabilities  $
-
   $2,796 
Schedule of Future Minimum Payments As of March 31, 2024, future minimum payments during the next five years and thereafter are as follows:
   Operating 
   Leases 
Remaining Period Ended December 31, 2024   560 
Year Ended December 31, 2025   685 
Year Ended December 31, 2026   685 
Year Ended December 31, 2027   685 
Year Ended December 31, 2028   766 
Thereafter   1,160 
Total   4,541 
Less present value discount   (1,193)
Operating lease liabilities  $3,348 
v3.24.1.u1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2024
Net Loss per Share [Abstract]  
Schedule of Computation of Diluted Loss Per Share Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2024, and 2023 are as follows:
   As of March 31, 
   2024   2023 
Convertible preferred stock   34    34 
Warrants to purchase common stock   444,796    444,796 
Restricted stock awards   136,309    
-
 
Options to purchase common stock   420,096    31,193 
Total   1,001,235    476,023 
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock (Tables)
3 Months Ended
Mar. 31, 2024
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Schedule of Warrant Activity A summary of warrant activity for the three months ended March 31, 2024, is presented below:
   Warrants   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of December 31, 2023   444,796   $29.25    
-
    2.20 
Granted   
-
   $
-
    
-
    
-
 
Outstanding as of March 31, 2024   444,796   $29.25    
-
    1.95 
Schedule of Restricted Stock Awards Activity A summary of restricted stock awards activity for the three months ended March 31, 2024, is presented below:
   Number of Restricted Stock Awards   Weighted Average Grant Day Fair Value 
Nonvested at December 31, 2023   136,309   $2.26 
Granted   
-
   $
-
 
Vested   
-
   $
-
 
Nonvested at March 31, 2024   136,309   $2.26 
Schedule of Stock Option Activity A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2024, is presented below:
   Number of Shares   Weighted Average Exercise Price   Total Intrinsic Value   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2023   420,168   $5.80   $
           -
    9.3 
Employee options expired   (72)  $6,410.74    
-
    
-
 
Outstanding as of March 31, 2024   420,096   $4.71   $
-
    9.0 
Options vested and exercisable   108,666   $8.37   $
-
    8.6 
v3.24.1.u1
Revenue (Tables)
3 Months Ended
Mar. 31, 2024
Revenue [Abstract]  
Schedule of Total Revenues Disaggregated by Revenue Type The following table presents our total revenue disaggregated by revenue type for the three months ended March 31, 2024 and 2023 (in thousands):
   Three Months Ended
March 31
 
   2024   2023 
Underwriting  $409   $
-
 
Commissions   310    
-
 
Advisory fees   341    
-
 
Other   307    
-
 
Total  $1,367   $
-
 
v3.24.1.u1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations.
   Three Months Ended
March 31, 2024
 
   Dominari
Financial
   Legacy
AIkido
   Consolidated 
Revenue  $1,367   $
-
   $1,367 
Operating Costs               
General and administrative   2,712    1,460   $4,172 
Loss from operations  $(1,345)  $(1,460)  $(2,805)
                
Other income (expenses)               
Other income   
-
    
-
    
-
 
Interest income   137    27    164 
Gain on marketable securities   
-
    574    574 
Realized and unrealized gain and loss on notes receivable, net   
-
    (915)   (915)
    Change in fair value of long-term equity investments        (2,459)   (2,459)
Total other income (expenses)  $137   $(2,773)  $(2,636)
Net loss  $(1,208)  $(4,233)  $(5,441)
v3.24.1.u1
Organization and Description of Business and Recent Developments (Details) - USD ($)
$ in Millions
3 Months Ended
Oct. 04, 2022
Mar. 31, 2024
Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]      
Seller paid (in Dollars) $ 2.0    
Additional seller paid (in Dollars)   $ 1.4  
FPS Purchase Agreement [Member]      
Organization and Description of Business and Recent Developments [Line Items]      
Membership interests rate     100.00%
FPS Purchase Agreement [Member]      
Organization and Description of Business and Recent Developments [Line Items]      
Membership interests rate 20.00% 80.00%  
v3.24.1.u1
Summary of Significant Accounting Policies (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Summary of Significant Accounting Policies [Abstract]  
Money market funds $ 14.1
v3.24.1.u1
Marketable Securities (Details) - Schedule of Marketable Securities - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Schedule of Marketable Securities [Abstract]    
Realized loss $ (93) $ (56)
Unrealized gain (loss) 473 (130)
Dividend income 193 121
Total $ 574 $ (65)
v3.24.1.u1
Long-Term Equity Investments (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 30, 2024
Feb. 14, 2024
Long-Term Equity Investments (Details) [Line Items]    
Public offering price   $ 4
Subsequent Event [Member]    
Long-Term Equity Investments (Details) [Line Items]    
Redemption amount $ 3.5  
v3.24.1.u1
Long-Term Equity Investments (Details) - Schedule of Long-Term Investments - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis $ 20,922  
Long-term investments, Total 21,691 $ 24,150
Investment In Kerna Health Inc [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 2,140  
Long-term investments, Total 4,940 4,940
Investment in Kaya Now [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,500  
Long-term investments, Total
Investment in Tevva Motors [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,972  
Long-term investments, Total 2,794 2,794
Investment in ASP Isotopes [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,300  
Long-term investments, Total
Investment in Unusual Machines [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 1,075  
Long-term investments, Total 813 1,033
Investment in Qxpress [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,000  
Long-term investments, Total [1] 1,000 1,000
Investment in Masterclass [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 170  
Long-term investments, Total [1] 170 170
Investment in Kraken [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 597  
Long-term investments, Total [1] 597 597
Investment in Epic Games [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500  
Long-term investments, Total [1] 2,626 3,500
Investment in Tesspay [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 1,240  
Long-term investments, Total [2] 2,981 2,679
Investment in SpaceX [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500  
Long-term investments, Total [1] 3,500 4,867
Investment in Databricks [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,200  
Long-term investments, Total [1] 842 842
Investment in Discord [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 476  
Long-term investments, Total [1] 476 476
Investment in Thrasio [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 300  
Long-term investments, Total [1]   300
Investment in Automation Anywhere [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 476  
Long-term investments, Total [1] 476 476
Investment in Anduril [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476  
Long-term investments, Total $ 476 $ 476
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
[2] Investments made in these companies are through both an SPV and direct investments.
v3.24.1.u1
Notes Receivable (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Notes Receivable [Line Items]  
Interest income $ 63,000
Convergent Therapeutics, Inc. [Member]  
Notes Receivable [Line Items]  
Principal repayment 300
Unrealized gain 60,000
Raefan Industries LLC [Member]  
Notes Receivable [Line Items]  
Unrealized loss 1,000
American Innovative Robotics, LLC [Member]  
Notes Receivable [Line Items]  
Interest income 22,000
Unrealized loss $ 1,000
v3.24.1.u1
Notes Receivable (Details) - Schedule of Notes Receivable - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Convergent convertible note - current [Member]    
Notes receivable, at fair value    
Maturity Date Dec. 02, 2024  
Stated Interest Rate 8.00%  
Principal Amount $ 816  
Interest Receivable  
Fair Value $ 816  
Raefan Industries LLC [Member]    
Notes receivable, at fair value    
Maturity Date Dec. 31, 2024 Dec. 31, 2024
Stated Interest Rate 8.00% 8.00%
Principal Amount $ 389 $ 1,363
Interest Receivable 751 751
Fair Value $ 1,139 $ 2,114
American Innovative Robotics [Member]    
Notes receivable, at fair value    
Maturity Date Apr. 01, 2027 Apr. 01, 2027
Stated Interest Rate 8.00% 8.00%
Principal Amount $ 1,106 $ 1,106
Interest Receivable 22 22
Fair Value 1,128 1,129
Notes receivable, at fair value - current portion [Member]    
Notes receivable, at fair value    
Fair Value 1,955 3,177
Notes receivable, at fair value - non-current portion [Member]    
Notes receivable, at fair value    
Fair Value $ 1,128 $ 1,129
Convergent convertible note - current [Member]    
Notes receivable, at fair value    
Maturity Date   Dec. 02, 2024
Stated Interest Rate   8.00%
Principal Amount   $ 1,006
Interest Receivable   58
Fair Value   $ 1,064
v3.24.1.u1
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Assets and Liabilities are Measured at Fair Value - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Marketable securities:    
Equities $ 5,123 $ 13,547
Total marketable securities 5,123 13,547
Notes receivable at fair value, current portion 1,955 3,177
Notes receivable at fair value,non-current portion 1,128 1,129
Short-term investment   1,128
Quoted prices in active markets (Level 1) [Member]    
Marketable securities:    
Equities 5,123 13,547
Total marketable securities 5,123 13,547
Notes receivable at fair value, current portion
Notes receivable at fair value,non-current portion  
Short-term investment  
Significant other observable inputs (Level 2) [Member]    
Marketable securities:    
Equities
Total marketable securities
Notes receivable at fair value, current portion
Notes receivable at fair value,non-current portion  
Short-term investment  
Significant unobservable inputs (Level 3) [Member]    
Marketable securities:    
Equities
Total marketable securities
Notes receivable at fair value, current portion 1,955 3,177
Notes receivable at fair value,non-current portion $ 1,128 1,129
Short-term investment   $ 1,128
v3.24.1.u1
Fair Value of Financial Assets and Liabilities (Details) - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis - Level 3 [Member]
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]  
Notes receivable at fair value, current portion, Balance beginning $ 3,177
Notes receivable at fair value, current portion at Balance ending 1,955
Notes receivable at fair value, non-current portion Balance beginning 1,129
Notes receivable at fair value, non-current portion Balance ending 1,128
Collection of principal outstanding (250)
Realized and unrealized gain and loss on note receivable, net (915)
Change in interest receivable (57)
Unrealized loss on notes receivable $ (1)
v3.24.1.u1
Leases (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 11, 2023
Sep. 23, 2022
Mar. 31, 2024
Mar. 31, 2023
Jul. 11, 2022
Leases [Abstract]          
Lease term   7 years     7 years
Rent expenses $ 12,874        
Increase rent amount   $ 51,868 $ 13,502    
Rent payment   $ 49,368      
Lease expenses     $ 200 $ 200  
Future minimum payments lease term     5 years    
v3.24.1.u1
Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets:    
Operating lease right-of-use-assets $ 3,242 $ 3,335
Liabilities:    
Operating current 419 421
Long-term    
Operating non-current 2,929 $ 3,028
Total $ 3,348  
v3.24.1.u1
Leases (Details) - Schedule of Summarize Quantitative Information about the Company’s Operating Leases
Mar. 31, 2024
Mar. 31, 2023
Schedule of Summarize Quantitative Information about the Company’s Operating Leases [Line Items]    
Weighted-average remaining lease term – operating leases (in years) 6 years 2 months 12 days 7 years 2 months 12 days
Weighted-average discount rate – operating leases 10.00% 10.00%
v3.24.1.u1
Leases (Details) - Schedule of Lease Expense - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating leases    
Operating lease cost $ 178 $ 134
Operating lease expense 178 134
Short-term lease rent expense 22 30
Net rent expense $ 200 $ 164
v3.24.1.u1
Leases (Details) - Schedule of Supplemental Cash Flow Information Related to Leases - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Schedule of Supplemental Cash Flow Information Related to Leases [Abstract]    
Operating cash flows - operating leases $ 187 $ 34
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,796
v3.24.1.u1
Leases (Details) - Schedule of Future Minimum Payments
$ in Thousands
Mar. 31, 2024
USD ($)
Schedule of Future Minimum Payments [Abstract]  
Remaining Period Ended December 31, 2024 $ 560
Year Ended December 31, 2025 685
Year Ended December 31, 2026 685
Year Ended December 31, 2027 685
Year Ended December 31, 2028 766
Thereafter 1,160
Total 4,541
Less present value discount (1,193)
Operating lease liabilities $ 3,348
v3.24.1.u1
Net Loss Per Share (Details) - Schedule of Computation of Diluted Loss Per Share - shares
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 1,001,235 476,023
Convertible preferred stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 34 34
Warrants to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 444,796 444,796
Restricted stock awards [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 136,309
Options to purchase common stock [Member]    
Schedule of Computation of Diluted Loss Per Share [Abstract]    
Total diluted loss per share 420,096 31,193
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Stockholders’ Equity and Convertible Preferred Stock [Line Items]      
Common stock, shares issued (in Shares) 5,995,065   5,995,065
Common stock, shares outstanding (in Shares) 5,934,917   5,934,917
Treasury stock shares (in Shares) 60,148   60,148
Share based compensation expense $ 100 $ 5,000  
unrecognized stock-based compensation expense 200    
Estimated future stock-based compensation expense 400    
Restricted Stock Awards [Member]      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]      
Share based compensation expense $ 75,000 $ 257  
Common Stock [Member]      
Stockholders’ Equity and Convertible Preferred Stock [Line Items]      
Common stock, shares issued (in Shares) 5,995,065    
Common stock, shares outstanding (in Shares) 5,934,917    
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Schedule of Warrant Activity [Line Items]    
Number of shares, ending balance 444,796 444,796
Weighted Average per share, ending balance $ 29.25 $ 29.25
Outstanding ending balance, Total Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life 1 year 11 months 12 days 2 years 2 months 12 days
Granted, Warrants  
Granted, Weighted Average Exercise Price  
Granted, Total Intrinsic Value  
Granted, Weighted Average Remaining Contractual Life  
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Restricted Stock Awards Activity
3 Months Ended
Mar. 31, 2024
$ / shares
shares
Schedule of Restricted Stock Awards Activity [Abstract]  
Number of shares, beginning balance | shares 136,309
Weighted Average per share, beginning balance | $ / shares $ 2.26
Number of shares, ending balance | shares 136,309
Weighted Average per share, ending balance | $ / shares $ 2.26
Number of Restricted Stock Awards, Granted | shares
Weighted Average Grant Day Fair Value, Granted | $ / shares
Number of Restricted Stock Awards, Vested | shares
Weighted Average Grant Day Fair Value, Vested | $ / shares
v3.24.1.u1
Stockholders’ Equity and Convertible Preferred Stock (Details) - Schedule of Stock Option Activity - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Schedule of Stock Option Activity [Abstract]    
Outstanding ending balance, Number of Shares 420,096 420,168
Outstanding ending balance, Weighted Average Exercise Price $ 4.71 $ 5.8
Outstanding ending balance, Intrinsic Value
Outstanding ending balance, Weighted Average Remaining Contractual Life 9 years 9 years 3 months 18 days
Number of Shares, Options vested and exercisable 108,666  
Weighted Average Exercise Price, Options vested and exercisable $ 8.37  
Total Intrinsic Value, Options vested and exercisable  
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable 8 years 7 months 6 days  
Employee options expired, Number of Shares (72)  
Employee options expired, Weighted Average Exercise Price $ 6,410.74  
Employee options expired, Intrinsic Value  
Employee options expired , Weighted Average Remaining Contractual Life  
v3.24.1.u1
Revenue (Details) - Schedule of Total Revenues Disaggregated by Revenue Type - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Schedule of Total Revenues Disaggregated by Revenue Type [Abstract]    
Underwriting $ 409
Commissions 310
Advisory fees 341
Other 307
Total $ 1,367
v3.24.1.u1
Regulatory (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Regulatory [Line Items]  
Net capital amount $ 0.1
Excess amount 13.3
Dominari Securities [Member]  
Regulatory [Line Items]  
Net capital amount $ 13.4
v3.24.1.u1
Related Party Transaction (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Related Party Transaction [Abstract]    
Incurred fees $ 0 $ 80,000
v3.24.1.u1
Segment Reporting (Details)
3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Reportable segments 2
v3.24.1.u1
Segment Reporting (Details) - Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Dominari Financial [Member]  
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]  
Revenue $ 1,367
Operating Costs  
General and administrative 2,712
Loss from operations (1,345)
Other income (expenses)  
Other income
Interest income 137
Gain on marketable securities
Realized and unrealized gain and loss on notes receivable, net
Total other income (expenses) 137
Net loss (1,208)
Legacy AIkido [Member]  
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]  
Revenue
Operating Costs  
General and administrative 1,460
Loss from operations (1,460)
Other income (expenses)  
Other income
Interest income 27
Gain on marketable securities 574
Realized and unrealized gain and loss on notes receivable, net (915)
Change in fair value of long-term equity investments (2,459)
Total other income (expenses) (2,773)
Net loss (4,233)
Consolidated [Member]  
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenues and Net Loss [Line Items]  
Revenue 1,367
Operating Costs  
General and administrative 4,172
Loss from operations (2,805)
Other income (expenses)  
Other income
Interest income 164
Gain on marketable securities 574
Realized and unrealized gain and loss on notes receivable, net (915)
Change in fair value of long-term equity investments (2,459)
Total other income (expenses) (2,636)
Net loss $ (5,441)
v3.24.1.u1
Income Taxes (Details) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Taxes [Abstract]    
Income tax expense

Dominari (NASDAQ:DOMH)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Dominari Charts.
Dominari (NASDAQ:DOMH)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Dominari Charts.